Search Results

You are looking at 1 - 10 of 23 items for

  • Author: M Hill x
  • Refine by access: All content x
Clear All Modify Search
M. J. Parkes
Search for other papers by M. J. Parkes in
Google Scholar
PubMed
Close
and
D. J. Hill
Search for other papers by D. J. Hill in
Google Scholar
PubMed
Close

ABSTRACT

Fetal lambs were hypophysectomized and, after 8 days of recovery, given infusions of GH, prolactin, thyroxine and insulin with glucose. Hypophysectomy caused no consistent reduction in fetal plasma somatomedin-like activity. Fetal infusions of GH or prolactin caused no consistent change in plasma somatomedin-like activity. It was concluded that fetal somatomedin-like activity is not GH dependent. After hypophysectomy fetal lambs showed no reduction in body weight or length at term.

J. Endocr. (1985) 104, 193–199

Restricted access
J Šulcová
Search for other papers by J Šulcová in
Google Scholar
PubMed
Close
,
M Hill
Search for other papers by M Hill in
Google Scholar
PubMed
Close
,
R Hampl
Search for other papers by R Hampl in
Google Scholar
PubMed
Close
, and
L Stárka
Search for other papers by L Stárka in
Google Scholar
PubMed
Close

Abstract

Dehydroepiandrosterone sulphate (DHEAS) and unconjugated dehydroepiandrosterone (DHEA) have been determined in the blood serum of normal subjects of both sexes from 1 month to 100 years of age. In total, 92 girls, 49 boys, 211 women and 110 men were investigated. The effects of age and sex on the levels of the hormones were measured.

DHEAS levels declined rapidly during the first year of life and were maintained at a minimum level for 5 years. They increased significantly from 6 to 7 years of age and reached maximum levels in women at about 24 years and in men at about 30 years of age. They then declined rapidly in both sexes but the fall which occurred after 50 and 60 years of age respectively was only moderate. Age-related unconjugated DHEA levels were different. After the first month of life DHEA levels were relatively high and declined more slowly. The minimum level was observed in girls between 5 and 7 years and in boys between 5 and 9 years of age. A significant rise then began and levels reached a maximum in women as well as in men at about 20 years of age. In men levels then declined up to the age of 80. In women the DHEA levels declined during the next 15 years and from approximately 36 years of age they again rose significantly up to a second peak. A mild but significant decline then resumed.

There was a difference in the levels of DHEA and DHEAS depending on sex. Unlike DHEAS, unconjugated DHEA was higher in women than in men. However, this difference was significant only in some age groups: during puberty (between 11 and 15 years of age), in the premenopausal period (between 36 and 45 years of age) and in the older group (after 60 years of age).

Age- and sex-related dependencies were different between DHEAS and DHEA. They indicate the possible variable secretion and dynamics of their (inter)conversion. We have concluded that DHEA measurements cannot be a substitute for DHEAS and vice versa.

Journal of Endocrinology (1997) 154, 57–62

Restricted access
D. J. Hill
Search for other papers by D. J. Hill in
Google Scholar
PubMed
Close
,
A. Logan
Search for other papers by A. Logan in
Google Scholar
PubMed
Close
,
M. McGarry
Search for other papers by M. McGarry in
Google Scholar
PubMed
Close
, and
D. De Sousa
Search for other papers by D. De Sousa in
Google Scholar
PubMed
Close

ABSTRACT

Chondrogenesis is thought to be controlled by interactions between circulating anabolic hormones and locally produced peptide growth factors, and involves ordered changes in matrix composition which ultimately allow endochondral calcification. We have used a model of isolated ovine fetal growth-plate chondrocytes to examine the actions and interactions of basic fibroblast growth factor (basic FGF), insulin-like growth factors-I and -II (IGF-I and -II), insulin and transforming growth factor-β1 (TGF-β1) on total protein, collagen or non-collagenous protein and sulphated glycosaminoglycan synthesis. These parameters were determined by assessment of the incorporation by monolayer cultures of early passage chondrocytes of [3H]leucine, [14C]proline and [35S]sulphate respectively, followed by partial molecular characterization. Basic FGF enhanced total protein synthesis with a half-maximal effective concentration of 270 ± 60 pmol/l (mean ± s.e.m., four animals) and was sixfold more active on a molar basis than IGF-I or insulin, and 28-fold more active that IGF-II which is the endogenously synthesized IGF. The actions of basic FGF were additive to those of IGF-I or insulin. More detailed analysis of extracellular-matrix component synthesis showed that basic FGF, IGF-I and insulin each caused significant increases in the synthesis of collagen and sulphated glycosaminoglycans. TGF-β1 had no effect on total protein synthesis by chondrocytes when present alone at concentrations of 200 pmol/l or less, but was inhibitory at 400 pmol/l. However, the use of this parameter masked a stimulatory action of 50 or 100 pmol TGF-β1 on sulphated glycosaminoglycan synthesis and a relative shift in the ratio of collagen: non-collagenous protein synthesis in favour of the former. A synergistic interaction existed between TGF-β1 (20–100 pmol/l) and basic FGF which potentiated total protein and collagen synthesis, and their actions on sulphated glycosaminoglycan production were additive. The same concentrations of TGF-β1 inhibited the ability of IGF-I or insulin to stimulate total protein or collagen synthesis, but were additive to their stimulatory effects on sulphated glycosaminoglycan synthesis. The results suggest that matrix-molecule composition and the anabolic status of the epiphyseal growth-plate may be modulated in utero by multiple interactions between peptide growth factors produced locally, such as basic FGF, IGF-II and TGF-β1, and circulating hormones such as insulin and IGF-I.

Journal of Endocrinology (1992) 133, 363–373

Restricted access
M N Hodgkin
Search for other papers by M N Hodgkin in
Google Scholar
PubMed
Close
,
C E Hills Department of Biological Sciences, Department of Infection, University of Warwick, Coventry CV4 7AL, UK

Search for other papers by C E Hills in
Google Scholar
PubMed
Close
, and
P E Squires
Search for other papers by P E Squires in
Google Scholar
PubMed
Close

In the 15 years since the identification and characterisation of the extracellular calcium-sensing receptor (CaR), it has become increasingly apparent that this cationic binding receptor is found in many tissues, not associated with the control of plasma calcium. One of these tissues is the pancreatic islet where insulin secretion provides the basis of energy regulation. It seems inherently unlikely that the islet responds to alterations in systemic calcium and a more plausible and intriguing possibility is that the CaR mediates cell-to-cell communication through local increases in the concentration of extracellular Ca2 +, co-released with insulin. This short article explores this possibility and suggests that this novel mechanism of cell communication, along with direct coupling via gap junctions and other local paracrine regulators helps explain why the glucose responsiveness of the intact islet is greater than the sum of the composite parts in isolation.

Free access
C Hill
Search for other papers by C Hill in
Google Scholar
PubMed
Close
,
A Flyvbjerg
Search for other papers by A Flyvbjerg in
Google Scholar
PubMed
Close
,
R Rasch
Search for other papers by R Rasch in
Google Scholar
PubMed
Close
,
M Bak
Search for other papers by M Bak in
Google Scholar
PubMed
Close
, and
A Logan
Search for other papers by A Logan in
Google Scholar
PubMed
Close

Diabetic nephropathy is characterised by an increase in glomerular and tubular fibrosis that compromises kidney function. The transforming growth factor-betas (TGF-betas) have been shown to play a major role in fibrosis and we have shown that TGF-beta2, in particular, increases co-ordinately with fibrogenesis in the diabetic kidney. The aim of this study was to investigate the changes in expression of extracellular matrix molecules in the diabetic kidney, with and without systemic administration of a recombinant human monoclonal antibody to TGF-beta2. Streptozotocin-induced diabetic rats were split into two groups. The first were treated with 5 mg/kg irrelevant control IgG4 (placebo) and the second treated with 5 mg/kg isoform-specific recombinant monoclonal anti-TGF-beta2 IgG4 (termed CAT-152) systemically every second day for 14 days. A further group of six non-diabetic rats was also used as a control. Various biological parameters were measured daily throughout the experimental period, and on termination of the experiment at 14 days Western blotting was performed on kidney cortices for procollagen-I C-propeptide, which is an indicator of the rate of collagen-I synthesis within the kidney. In the placebo-treated diabetic rats, blood glucose, food consumption, urinary albumin excretion (UAE) and kidney weights were all significantly higher than in the non-diabetic group (P<0.05, n=24, by ANOVA). In the anti-TGF-beta2-treated diabetic rats, kidney weights and UAE levels were decreased when compared with those in placebo-treated diabetics. Western blotting for the procollagen-I C-propeptide in kidney cortices showed a significant increase in levels in placebo-treated diabetic rats compared with non-diabetic controls over the 14 day diabetic period, indicating initiation of fibrogenesis. By contrast, in anti-TGF-beta2-treated diabetic rats, levels of the propeptide remained at non-diabetic levels. In summary, a significant suppression of kidney fibrosis was seen in anti-TGF-beta2-treated diabetic rats, compared with placebo-treated diabetic rats. We conclude that systemic delivery of CAT-152, a neutralising anti-TGF-beta2 antibody, during the acute stages of diabetic nephropathy reduces the rate of pathogenic fibrosis in the kidney.

Free access
W. M. Bennet
Search for other papers by W. M. Bennet in
Google Scholar
PubMed
Close
,
S. F. Hill
Search for other papers by S. F. Hill in
Google Scholar
PubMed
Close
,
M. A. Ghatei
Search for other papers by M. A. Ghatei in
Google Scholar
PubMed
Close
, and
S. R. Bloom
Search for other papers by S. R. Bloom in
Google Scholar
PubMed
Close

ABSTRACT

Galanin-like immunoreactivity (IR) was measured by radioimmunoassay in extracts of non-tumorous and tumorous human pituitaries and in multiple sites in the human brain. Galanin-IR was present in considerable quantities in the non-tumorous pituitaries (21·4±1·2 pmol/g wet weight; mean ± s.e.m., n = 30). In 25 pituitary tumours, galanin-IR was detectable in extracts of only nine, with a mean concentration of 11·5±4·4 pmol/g. Galanin-IR was undetectable in the remaining 16. Of ten brain sites, galanin-IR was detected only in the hypothalamus, where the concentration was 9·1±1·8 pmol/g (n = 5). On fast protein liquid chromatography of the non-tumorous pituitary extracts, galanin-IR mostly eluted in a peak with a retention time similar to that of synthetic porcine galanin. On gel permeation chromatography, galanin-IR eluted as a peak with an elution coefficient (K av) of 0·72, also similar to that of porcine galanin, with additional preceding (K av 0·62) and following (K av 0·77) peaks of galanin-IR. These results show that healthy human pituitary and hypothalamus contain substantial amounts of galanin, whereas it is present in variable amounts or not at all in pituitary tumours. Chromatographic analysis suggests that pituitary galanin is present in three molecular forms, with the majority corresponding to synthetic porcine galanin.

Journal of Endocrinology (1991) 130, 463–467

Restricted access
F A Hills
Search for other papers by F A Hills in
Google Scholar
PubMed
Close
,
M G Elder
Search for other papers by M G Elder in
Google Scholar
PubMed
Close
,
T Chard
Search for other papers by T Chard in
Google Scholar
PubMed
Close
, and
M H F Sullivan
Search for other papers by M H F Sullivan in
Google Scholar
PubMed
Close

Many studies have implicated the insulin-like growth factors (IGFs) and insulin-like growth factor-binding protein-1 (IGFBP-1) in the control of the feto–maternal interface of human pregnancy, but many of the data are from cell lines derived from primary trophoblast or from extravillous trophoblast. We have obtained highly enriched villous cytotrophoblast (VCT) from first trimester and term human placentae, and investigated the effects of IGF-I, IGF-II and phosphoisoforms of IGFBP-1. First trimester villous trophoblast cells were regulated by all these factors. IGF-II increased cell numbers 3.5-fold after 96 h in culture, and IGF-I had less effect (1.5-fold increase) (both P<0.05). IGF-II also had a greater effect on the levels of matrix metalloproteinase (MMP)-2 and MMP-9. Phosphorylated and non-phosphorylated iso-forms of IGFBP-1 added alone increased cell numbers and MMP levels (P<0.05). IGFBP-1 did not modify the effects of IGF-II on cell numbers or on MMP production. Term VCT numbers and MMP production in vitro were unaffected by IGFs (P>0.05). Cell numbers were increased only by 100 nM IGFBP-1 isoforms (P<0.05), whereas MMP levels released from term cells were optimally increased by 1–10 nM IGFBP-1. Overall, our data show that IGFs regulate only first trimester, but not term, VCT. IGFBP-1 regulates VCT from both gestations, but the effects are concentration and end-point specific. In particular, first trimester cell numbers are more affected by low levels of IGFBP-1, whereas high levels of IGFBP-1 are needed to increase MMP and the converse applies to term VCT; low levels of IGFBP-1 have more effect on MMP levels.

Free access
J. Hogg
Search for other papers by J. Hogg in
Google Scholar
PubMed
Close
,
V. K. M. Han
Search for other papers by V. K. M. Han in
Google Scholar
PubMed
Close
,
D. R. Clemmons
Search for other papers by D. R. Clemmons in
Google Scholar
PubMed
Close
, and
D. J. Hill
Search for other papers by D. J. Hill in
Google Scholar
PubMed
Close

ABSTRACT

Insulin is a major regulatory hormone for optimal tissue growth and function in utero. Its continued availability to the growing fetus depends on increasing islet cell mass. The purpose of the study was to examine the interactions between nutrient availability and insulin-like growth factor (IGF) release and action during DNA synthesis by isolated fetal rat islets of Langerhans. Specifically, we wished to determine (a) whether the availability of glucose or total amino acids altered the release of endogenous IGF-I or -II, (b) if both IGF-I and -II were effective mitogens for pancreatic β-cells, (c) whether islets released IGF-binding proteins (IGFBPs) and their possible regulation by nutrient availability and (d) how IGFBPs might regulate the ability of IGFs to alter islet DNA synthesis. Islets of Langerhans were isolated from fetal rat pancreata on day 22 of gestation by collagenase digestion. Islets enriched in β-cells following a 5-day preincubation regime were maintained in various concentrations of glucose (1·4–16·7 mmol/l) or amino acids (×1–×3 total concentrations), with or without exogenous IGF-I, -II, IGFBP-1 or IGFBP-2. The release of insulin and endogenous IGF-I and -II were each determined by radioimmunoassay, and IGFBP release characterized by Western ligand blot analysis. DNA synthesis was measured by the incorporation of [3H]thymidine. Isolated islets demonstrated an increased release of insulin in response to increasing amounts of both glucose and amino acids, demonstrating functional viability. Both classes of nutrients also increased the DNA synthetic rate of islets. Islets released almost twice as much IGF-II (0·22 ± 0·08 nmol/l, mean ± s.e.m., n=4) as IGF-I (0·14 ± 0·03 nmol/l) in cultures containing 8·7 mmol glucose/1 and × 1 amino acids. Lesser or greater concentrations of glucose did not alter the release of either IGF, but the release of IGF-II was significantly increased (0·53 ± 0·08 nmol/l, P<0·01) in the presence of × 2 amino acids. Exogenous IGF-I was fivefold more active in stimulating DNA synthesis by islets (half maximal concentration (ED50) 1·6 ± 0·4 nmol/l, n = 3) than was IGF-II (ED50 8·1 ± 0·6 nmol/l), regardless of glucose concentration. Isolated islets released four species of IGFBP with molecular sizes of approximately 19, 25, 35 and 46 kDa respectively. The 35 kDa form was identified by Western immunoblot as IGFBP-2. Increasing the glucose concentration between 1·4 mmol/l and 16·7 mmol/l caused a dose-related increase in the release of the 19, 25 and 35 kDa IGFBP species. Increasing amino acid concentrations from × 1 to × 2 concentrations increased the relative amounts of all IGFBP species, but greater concentrations were inhibitory. Exogenous IGFBP-1 and BP-2 synergized with sub-effective concentrations of IGF-I or -II to increase DNA synthetic rate. The results show that isolated fetal rat islets release more IGF-II than IGF-I, but that IGF-I is a more potent stimulus to DNA synthesis. The ability of glucose to increase islet DNA synthesis was not accompanied by altered release of endogenous IGFs, but did result in increased release of IGFBPs. Increasing the concentration of total amino acids increased the release of both IGF-II and IGFBPs. Since exogenous IGFBPs were able to potentiate the mitogenic actions of IGFs, it is likely that nutrients, IGFs and IGFBPs interact to promote islet cell hyperplasia in late gestation.

Journal of Endocrinology (1993) 138, 401–412

Restricted access
I. D. Phillips
Search for other papers by I. D. Phillips in
Google Scholar
PubMed
Close
,
E. Arany
Search for other papers by E. Arany in
Google Scholar
PubMed
Close
,
A. J. Strain
Search for other papers by A. J. Strain in
Google Scholar
PubMed
Close
,
V. K. M. Han
Search for other papers by V. K. M. Han in
Google Scholar
PubMed
Close
, and
D. J. Hill
Search for other papers by D. J. Hill in
Google Scholar
PubMed
Close

ABSTRACT

The presence of insulin-like growth factors (IGFs) in blood is regulated by their association with specific IGF-binding proteins (IGFBPs). In turn, the level of IGFBPs in the blood is likely to depend on a dynamic equilibrium between peptide production and clearance to extravascular tissues or organ-specific degradation. Since circulating IGFBPs may largely derive from liver we have employed partial hepatectomy in the rat to study the clearance rate of endogenous IGFBPs from blood once a major site of production is removed. Adult male rats were partially hepatectomized and serum and the remaining liver removed between 30 min and 7 days after surgery. Ligand blot analysis revealed two major species of IGFBP, of 28–30 kDa and 40–44 kDa in sera from control rats or sham-operated rats respectively. The larger species corresponded in size to rat IGFBP-3, but the smaller form was not recognized by antisera against rat IGFBP-1, bovine IGFBP-2 or human IGFBP-5 following Western immunoblot. Following hepatectomy, the levels of both IGFBP forms in the serum declined within 30 min and were barely detectable after 3 h or 6 h. They began to increase again in serum 24 h following surgery. The reduction in IGFBPs following hepatectomy was not primarily due to degradation by specific proteases in serum. Circulating levels of insulin were increased fivefold 3 h after hepatectomy but subsequently returned to control values. The rise in insulin was accompanied by a significant (P < 0·05) reduction in circulating IGF-I after 3 h which persisted at 24 h. Glucose levels in serum showed a transient but non-significant reduction between 90 min and 6 h after hepatectomy. Total RNA was extracted from remnant liver and subjected to Northern blot hybridization with 32P-labelled cDNAs encoding rat IGFBP-1, -2 or -3. Messenger RNA encoding IGFBP-1 was barely detectable in liver from control or sham-operated animals, but increased within 30 min of partial hepatectomy and peaked at 3 h. It subsequently declined and was again barely detectable after 24 h. No expression of IGFBP-2 or -3 mRNAs was found by Northern blot analysis in the liver of control animals or following partial hepatectomy. These results suggest that both IGF-I and IGFBPs in rat serum decreased rapidly following partial hepatectomy, and that this was due largely to the rapid clearance of the peptide and its binding proteins once the major source of production was removed. A rapid induction of IGFBP-1 in the remaining liver may be unrelated to the circulating IGFBPs since immunoreactive IGFBP-1 was not detected in rat serum.

Journal of Endocrinology (1993) 137, 271–280

Restricted access
D. J. HILL
Search for other papers by D. J. HILL in
Google Scholar
PubMed
Close
,
M. J. O. FRANCIS
Search for other papers by M. J. O. FRANCIS in
Google Scholar
PubMed
Close
, and
R. D. G. MILNER
Search for other papers by R. D. G. MILNER in
Google Scholar
PubMed
Close

Rat prolactin at a concentration of 50 ng/ml perfusion medium stimulated the production of somatomedin-like activity (SLA) from the perfused liver of normal rats. The effect was demonstrable in perfusions performed at 11.00 h in which rat prolactin caused a mean (±s.e.m.) increase in the uptake of [35S]sulphate into rat costal cartilage in vitro of 64 ± 14% in comparison with controls, but at 15.00 h no effect was observed. No effect of rat prolactin on hypophysectomized rat liver was detectable at 11.00 h.

Hypophysectomized and sham-operated rats were given five intravenous injections of 50 μg rat prolactin or a similar volume of hormone solvent at 12 h intervals. Plasma somatomedin activity (SMA) and cartilage metabolism, measured by the uptake of radioactive sulphate and thymidine by costal cartilage in vitro, were similar in hypophysectomized animals given rat prolactin or hormone solvent. Sham-operated rats given rat prolactin showed a significant increase of plasma SMA and cartilage metabolism compared with control animals.

The production of SLA by rat liver in response to rat prolactin may be related to the density of specific hepatic lactogenic receptors, since these are absent or present only in low numbers in hypophysectomized animals.

Restricted access